Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Retained Earnings (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Retained Earnings for 14 consecutive years, with $71000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 100.0% year-over-year to $71000.0, compared with a TTM value of $71000.0 through Dec 2025, up 100.0%, and an annual FY2025 reading of $71000.0, up 100.0% over the prior year.
  • Retained Earnings was $71000.0 for Q4 2025 at Karyopharm Therapeutics, up from -$1.7 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $71000.0 in Q4 2025 and bottomed at -$1.7 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$1.0 billion, with a median of -$1.3 billion recorded in 2022.
  • Peak annual rise in Retained Earnings hit 100.0% in 2025, while the deepest fall reached 746431.98% in 2025.
  • Year by year, Retained Earnings stood at -$1.2 billion in 2021, then decreased by 14.02% to -$1.3 billion in 2022, then dropped by 10.65% to -$1.5 billion in 2023, then dropped by 5.14% to -$1.6 billion in 2024, then skyrocketed by 100.0% to $71000.0 in 2025.
  • Business Quant data shows Retained Earnings for KPTI at $71000.0 in Q4 2025, -$1.7 billion in Q3 2025, and -$1.6 billion in Q2 2025.